2.97
0.07 (2.41%)
| Penutupan Terdahulu | 2.90 |
| Buka | 2.93 |
| Jumlah Dagangan | 56,429 |
| Purata Dagangan (3B) | 55,721 |
| Modal Pasaran | 1,061,909,888 |
| Harga / Pendapatan (P/E Ke hadapan) | 59.88 |
| Harga / Jualan (P/S) | 1.29 |
| Harga / Buku (P/B) | 1.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -26.26% |
| Margin Operasi (TTM) | -9.91% |
| EPS Cair (TTM) | -0.690 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -4.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 52.48% |
| Nisbah Semasa (MRQ) | 2.03 |
| Aliran Tunai Operasi (OCF TTM) | 34.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -90.11 M |
| Pulangan Atas Aset (ROA TTM) | -2.42% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Evotec SE | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -4.0 |
| Purata | 0.50 |
|
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Institusi | 2.56% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Pitcairn Co | 30 Sep 2025 | 161,769 |
| Snowden Capital Advisors Llc | 30 Sep 2025 | 29,053 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2025 | Pengumuman | Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership |
| 05 Nov 2025 | Pengumuman | Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities |
| 04 Nov 2025 | Pengumuman | In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties |
| 29 Oct 2025 | Pengumuman | Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025 |
| 27 Oct 2025 | Pengumuman | Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |